WHAT IS BCAR?
Blood and Cells Advocacy Roster
Providing Joint Voice for the Blood Industry.
Could your organization be part of BCAR?
BCAR is continuing to grow, and we are looking to bring more organizations, expertise and perspectives into the consortium as we move into our next phase.
Membership is an opportunity to be part of the conversations, content and collaborative initiatives BCAR is developing, and, importantly, to help shape what comes next.
If your organization works across the blood, cell, biotherapy or wider healthcare ecosystem and you are interested in joining the consortium, we would love to hear from you.
BCAR is shaped by the organizations around the table. If you think yours should be one of them, get in touch with Michelle today!
Blood is the foundation of modern medicine, but the organizations and people behind it have not always had a unified voice. BCAR - The Blood and Cells Advocacy Roster is working to change that by bringing together organizations from across the blood and cell ecosystem to share expertise, build a stronger collective narrative, and collaborate on projects that have the potential to address real challenges for the industry and the patients it serves.
MEMBERS
THE IMPORTANCE OF BLOOD
The Blood and Cells Advocacy Roster (BCAR), an industry consortium of blood therapy and cell and gene therapy starting materials stakeholders, aims to function as a think-tank plus speaker advocacy group. The international organization looks to drive the narrative on the importance of the established blood industry, particularly to help improve patient access to advanced therapies. BCAR will collaboratively propose solutions to tackle the complex challenges that could otherwise throttle development and commercial availability of life-saving cell and gene therapies.
Blood is recognized by the World Health Organization as an essential medicine. The blood industry’s infrastructure has been relied on for decades to manufacture and deliver blood-based therapies like transfusion and red blood cell exchange. These are safe, accepted clinical approaches to treat many diseases and conditions. More recently, the emergence of cell and gene therapies (CGTs) – often-curative treatments for dangerous diseases like late-stage blood cancers – has expanded the widespread reliance on blood systems, as a means of providing sources for starting materials. But the biopharma industry has been racing to keep up with demand, and struggling to manufacture them affordably, even while new therapies continue to reach the market for more diseases.
